drugset / Trial / NCT00221364

Trachoma Elimination Follow-up

NCT00221364

Phase 4 Completed 20000 enrolled University of California, San Francisco
RandomizedSingle-groupSingle-blindTreatment

Summary

The WHO has initiated a program to eliminate blinding trachoma by the year 2020, in large part by mass oral azithromycin distributions. It is not clear how frequently or for how long these treatments are necessary. Here we assess the frequency and duration of treatment.

Timeline

Start
2003-03
Primary completion
2005-04
Completion
2005-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule Oral

Indications